INDEMNIFICATION AGREEMENTIndemnification Agreement • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (the “Agreement”) is entered into as of by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”) and the undersigned party (the “Indemnitee”).
ACLARIS THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 30, 2014Investors’ Rights Agreement • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of this 30th day of September, 2014 (the “Effective Date”), by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series A Preferred Stock listed on Exhibit A attached hereto (the “Series A Holders”) and the holders of the Company’s Series B Preferred Stock listed on Exhibit B attached hereto (the “Series B Holders” and together with the Series A Holders, the “Investors”).
ASSIGNMENT AGREEMENTAssignment Agreement • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • California
THIS ASSIGNMENT AGREEMENT (the “Agreement”) is made effective as of August 20, 2012 (the “Effective Date”), by and between ACLARIS THERAPEUTICS, INC., a Delaware corporation, having an address of 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 (“Assignee”), and MICKEY J MILLER, II, of 5757 Preston View Blvd, Appt. #130, Dallas, Texas 75240, as Personal Representative of the estate of Mickey J. Miller (“Miller Estate”).
ACLARIS THERAPEUTICS, INC. STOCK OPTION GRANTStock Option Grant • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement (this “Agreement”) dated as of [ ] and effective as of [ ] (the “Grant Date”), between Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Grantee”), an employee of the Company. Capitalized terms used but not defined herein shall have the meaning set forth in the Plan (as defined below).
SERVICES AGREEMENTServices Agreement • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
THIS SERVICES AGREEMENT (the “Agreement”), effective as of February 5, 2014 (the “Effective Date”), between NST, LLC (“NST”), a Delaware limited liability company with its principal offices located at 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 and Aclaris Therapeutics, Inc. (“ACLARIS”), a Delaware corporation having a place of business at 101 Lindenwood Drive, Suite 400, Malvern, PA 19355 (each a “party”, collectively, the “parties”).
CLINICAL AND COMMERCIAL SUPPLY AGREEMENTClinical and Commercial Supply Agreement • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS CLINICAL AND COMMERCIAL SUPPLY AGREEMENT (this “Agreement”), effective as of August 6, 2014 (“Effective Date”), by and between PeroxyChem, a Delaware corporation, with a principal place of business at 1735 Market Street, Philadelphia, Pennsylvania 19103 (“PeroxyChem”) and Aclaris Therapeutics, Inc., a Delaware corporation, with a principal place of business at 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 (“Aclaris”).
FINDER’S SERVICES AGREEMENTFinder’s Services Agreement • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • California
THIS FINDER’S SERVICES AGREEMENT (the “Agreement”) is made effective as of August 25, 2012 (the “Effective Date”), by and between ACLARIS THERAPEUTICS, INC., a Delaware corporation, having an address of having an address of 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 (“Aclaris”), and KPT CONSULTING LLC, a Pennsylvania corporation, having an address of 1852 Glenwold Dr., Paoli, PA 19301 (“KPT”).
AMENDED AND RESTATED SUBLEASE BETWEEN NEXEPTION, INC. AND ACLARIS THERAPEUTICS, INC.Sublease • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
THIS Amended and Restated Sublease (“Sublease”) is effective as of the 3rd day of March 2014 by NeXeption, Inc., a Delaware corporation (“Sublandlord”), whose address is 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 and Aclaris Therapeutics, Inc., a Delaware corporation (“Subtenant”), whose address is 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355.
